ARTICLES & NEWS :Enzymotec

Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash FlowVAYA Pharma Generates Record Net Revenues of $2.2 Million MIGDAL HA'EMEQ, Is […]

Revenues and Adjusted EBITDA Increased for Fourth Consecutive Quarter Q2 Net Revenues Increased 49.5% Year-Over-Year; Q2 Net Income of $0.10 Per Diluted Share MIGDAL HA'EMEQ, Isra […]

MIGDAL HA'EMEQ, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results […]

MIGDAL HA'EMEQ, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results […]

Enhances Depth of Executives With Five New Hires Across the Company MIGDAL HA'EMEQ, Israel, Aug. 29, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) (the "Company") today announced that it has […]

MIGDAL HA'EMEQ, Israel, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced the initiation of a […]

You are about to enter a site that is for U.S. Healthcare Professionals only. By selecting "Yes" below, you certify that you are a Healthcare Professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the U.S. but may not be available in all other countries.

I am a licensed Healthcare Professional and wish to proceed to the Healthcare Professionals Only section of this site.